GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brii Biosciences Ltd (HKSE:02137) » Definitions » Price-to-Free-Cash-Flow

Brii Biosciences (HKSE:02137) Price-to-Free-Cash-Flow : N/A (As of Jun. 23, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Brii Biosciences Price-to-Free-Cash-Flow?

As of today (2024-06-23), Brii Biosciences's share price is HK$1.09. Brii Biosciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.89. Hence, Brii Biosciences's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Brii Biosciences's Price-to-Free-Cash-Flow or its related term are showing as below:

HKSE:02137's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 33.78
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Brii Biosciences's Free Cash Flow per Share for the six months ended in Dec. 2023 was HK$-0.36. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was HK$-0.89.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -12.60% per year.

During the past 5 years, Brii Biosciences's highest 3-Year average Free Cash Flow per Share Growth Rate was -12.60% per year. The lowest was -89.60% per year. And the median was -51.10% per year.


Brii Biosciences Price-to-Free-Cash-Flow Historical Data

The historical data trend for Brii Biosciences's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brii Biosciences Price-to-Free-Cash-Flow Chart

Brii Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
- - - - -

Brii Biosciences Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Brii Biosciences's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Brii Biosciences's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Brii Biosciences's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brii Biosciences's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Brii Biosciences's Price-to-Free-Cash-Flow falls into.



Brii Biosciences Price-to-Free-Cash-Flow Calculation

Brii Biosciences's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=1.09/-0.893
=N/A

Brii Biosciences's Share Price of today is HK$1.09.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Brii Biosciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.89.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Brii Biosciences  (HKSE:02137) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Brii Biosciences Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Brii Biosciences's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Brii Biosciences (HKSE:02137) Business Description

Traded in Other Exchanges
Address
No. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed towards developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as the CNS diseases, which have public health burdens in China and worldwide. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
Executives
Hong Zhi 2101 Beneficial owner
Xyxy Holdings Ltd. 2201 Interest of corporation controlled by you
Booming Passion Limited 2101 Beneficial owner
Boyu Capital Fund Iii, L.p. 2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, L.p. 2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, Ltd 2201 Interest of corporation controlled by you
Tong Xiaomeng 2201 Interest of corporation controlled by you
Boyu Group, Llc 2201 Interest of corporation controlled by you
Boyu Capital Group Holdings Ltd 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Invesco Advisers, Inc. 2102 Investment manager
Ma Yun 2201 Interest of corporation controlled by you
Yunfeng Investment Iii, Ltd. 2201 Interest of corporation controlled by you
Yunfeng Fund Iii, L.p. 2201 Interest of corporation controlled by you
Yf Bright Insight Limited 2101 Beneficial owner

Brii Biosciences (HKSE:02137) Headlines

No Headlines